id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-021966-5m21bsrw	Shaw, Alan R.	Vaccines	2009-05-15		.txt	text/plain	21170	897	33	Because a number of proteins produced in isolation by recombinant methods have been observed to elicit lower immune responses than do natural infections or live attenuated vaccines, the development and use of adjuvants to optimize recombinant vaccine immunogenicity represent an important parallel area for future exploration. Modern molecular biology and biochemistry have provided numerous options for vaccine immunogen presentation, including recombinant proteins (and recombinant virus-like particles (VLPs)), synthetic proteins, protein-polysaccharide conjugates, and gene delivery systems (recombinant viral vectors, or DNA vaccines) >> Is the antigen of interest sufficiently immunogenic on its own, or is augmentation of the desired immune response by conjugation to a specific carrier or addition of an adjuvant necessary to elicit a sufficient and sufficiently durable immune response in individuals in the target population for vaccination?	./cache/cord-021966-5m21bsrw.txt	./txt/cord-021966-5m21bsrw.txt